S. Leung

ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia

R. Chandler, C. Venditti, I. Manoli, 2021, Molecular therapy. Methods & clinical development.

Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles

T. Kishimoto, P. Ilyinskii, C. Roy, 2021, Science Advances.

Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia

T. Kishimoto, W. Dehaan, A. Kivitz, 2022, Nature Communications.

Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles leads to massive expansion of antigen-specific Tregs and protection against autoimmune disease

Jamie B. Spangler, P. Traber, Ning Li, 2023, bioRxiv.

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

S. Nicolaou, Hyon K. Choi, P. Traber, 2023, Rheumatology and Therapy.

Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.

P. Ilyinskii, C. Roy, D. VanDyke, 2023, Journal of autoimmunity.

Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents

P. Ilyinskii, C. Roy, S. Leung, 2023, PNAS nexus.